Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 7/20 | 0.67 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.37 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6770087 | 0.81 | PGR (1.00) | PGRTAAR1MAOBESR2ALOX5 | |
| SCHEMBL4367637 | 0.74 | PGR (0.70) | PGRTAAR1MAOBESR2ALOX5 | |
| SCHEMBL4352812 | 0.72 | PGR (0.60) | PGRTAAR1MAOBESR2ALOX5 | |
| SCHEMBL4357762 | 0.71 | PGR (0.67) | PGRTAAR1MAOBESR2ALOX5 | |
| SCHEMBL4540489 | 0.70 | PGR (0.65) | PGRTAAR1MAOBESR2ALOX5 | |
| SCHEMBL20781937 | 0.70 | TAAR1 (0.62) | PGRTAAR1MAOBESR2ALOX5 | |
| SCHEMBL18014701 | 0.68 | TAAR1 (0.50) | PGRTAAR1MAOBAOC3ESR2 | |
| SCHEMBL7489944 | 0.68 | DHFR (0.49) | PGRTAAR1MAOB | |
| SCHEMBL279178 | 0.67 | PGR (0.51) | PGRTAAR1ALOX5 | |
| SCHEMBL7496853 | 0.66 | PGR (0.55) | PGRTAAR1MAOBESR2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796266-B2 | Cyclothiocarbamate derivatives as progesterone receptor modulators | WYETH LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-20130261112-A1 | Cyclothiocarbamate Derivatives as Progesterone Receptor Modulators | WYETH LLC | 2013-10-03 | — | — | US | disclosed |
| US-8466146-B2 | Cyclothiocarbamate derivatives as progesterone receptor modulators | WYETH LLC (US) | 2013-06-18 | — | — | US | disclosed |
| US-20130072480-A1 | Cyclothiocarbamate Derivatives as Progesterone Receptor Modulators | WYETH LLC (US) | 2013-03-21 | — | — | US | disclosed |
| US-7081457-B2 | Contraceptives; hormone replacement therapy | WYETH (US) | 2006-07-25 | — | — | US | disclosed |
| US-6759408-B2 | CYCLIC COMBINATION THERAPIES AND REGIMENS UTILIZING SUBSTITUTED INDOLINE DERIVATIVE COMPOUNDS WHICH ARE ANTAGONISTS OF THE PROGESTERONE RECEPTOR | WYETH | 2004-07-06 | — | — | US | disclosed |
| US-6566358-B2 | 1,4-dihydro-benzo(d)oxazin-2-one derivatives useful for treating hormone-dependent neoplastic disease is selected from uterine myometrial fibroids, endometriosis, benign prostatic hypertrophy, carcinomas, and adenocarcinoma | WYETH | 2003-05-20 | — | — | US | disclosed |
| US-20030092711-A1 | Contraceptives; hormone replacement therapy | WYETH LLC | 2003-05-15 | — | — | US | disclosed |
| US-20030045511-A1 | Combination regimens using progesterone receptor modulators | WYETH | 2003-03-06 | — | — | US | disclosed |
| US-6444668-B1 | IN COMBINATION WITH A PROGESTIN, AN ESTROGEN, OR BOTH; ANTIPROGESTIN IS A 1,4-DIHYDRO-BENZO(D)(1.3)OXAZIN-2-ONE | WYETH | 2002-09-03 | — | — | US | disclosed |
| US-6436929-B1 | 3,1-BENZOXAZINE-2-THIONES; CONTRACEPTION AND THE TREATMENT OF PROGESTERONE-RELATED MALADIES | WYETH | 2002-08-20 | — | — | US | disclosed |
| US-20020049204-A1 | Cyclocarbamate derivatives as progesterone receptor modulators | WYETH | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045511-A1 | Combination regimens using progesterone receptor modulators | GNRHR, PGR, PRLHR | PGR 2/4885TAAR1 114/4885MAOB 2571/4885 |
| US-20030092711-A1 | Contraceptives; hormone replacement therapy | PGR, GNRHR, GHRHR | PGR 1/4885TAAR1 379/4885MAOB 654/4885 |
| US-20130072480-A1 | Cyclothiocarbamate Derivatives as Progesterone Receptor Modulators | PGR, PGRMC2, PGRMC1 | PGR 1/4885TAAR1 287/4885MAOB 3456/4885 |
| US-20130261112-A1 | Cyclothiocarbamate Derivatives as Progesterone Receptor Modulators | PGR, PGRMC2, PGRMC1 | PGR 1/4885TAAR1 287/4885MAOB 3456/4885 |
| US-20020049204-A1 | Cyclocarbamate derivatives as progesterone receptor modulators | NR3C1, NR5A1, CNR1 | PGR 5/4885TAAR1 260/4885MAOB 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.